Physician profile
Yang Liu
NPI 1033430913
$6,251.89
in general payments reported to CMS, 2019-2025
21 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $118 · 2021: $217 · 2022: $301 · 2023: $610 · 2024: $1,610 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.82 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $1,020.88 | 2024-2025 | Voquezna |
| Abbvie INC. | $863.16 | 2019-2024 | |
| Gilead Sciences, INC. | $775.27 | 2022-2025 | Vemlidy, Livdelzi |
| Madrigal Pharmaceuticals | $638.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $592.18 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $494.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.68 | 2021-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Janssen Biotech, INC. | $163.59 | 2025 | Simponi, Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $163.19 | 2024 | Zeposia |
| Novo Nordisk INC | $159.54 | 2025 | Wegovy |
| Steris Corporation | $141.55 | 2024 | |
| Allergan, INC. | $139.40 | 2019 | |
| Covidien LP | $124.99 | 2019 | |
| Dova Pharmaceuticals | $122.62 | 2019 | |
| Shire North American Group INC | $122.60 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.09 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $100.61 | 2023 | Dupixent |
| Medtronic, INC. | $97.38 | 2021 | |
| Shionogi INC | $95.62 | 2019 | |
| Boston Scientific Corporation | $70.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yang Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.